Global Influenza Vaccine Market - Trends & Forecast, 2018-2025

EXRHC003  |  July 2018  |  Global  |  80 Pages  |  Published

As of 2017, the Influenza Vaccine market was valued at USD xx million and is projected to reach USD xx million by 2025,growing at a CAGR of xx%. As the world moves towards an aging population, people’s susceptibility to influenza increases, raising demand for flu vaccines. Also improving healthcare systems, growing flu awareness and high birth rates in developing countries will fuel demand for existing and new influenza vaccines from 2017. The influenza vaccination industry thus holds great potential for progress and high sales. Vaccination is a stressful event, especially for children, and the company that can provide a uniquely non-stress vaccination will reap high rewards. The influenza virus changes each year and new vaccines are required to maintain immunization against the infection. With this in mind, the influenza vaccine market can be assured of high demand. And the development of a universal influenza vaccine that provides protection against seasonal and pandemic strains of the virus could potentially transform the industry. The influenza vaccines market is oligopolistic (few) in nature, with only 4 major pharmaceutical companies dominating the industry: Sanofi Pasteur, Seqirus, GSK and AstraZeneca. Sanofi held the largest share in the market with its bestselling influenza vaccine, Vaxigrip/Fluzone HD/Fluzone. It accounted for xx% in 2017 and is anticipated to maiantain its dominance throughout the forecast period. In Influenza Vaccine market by type segmentation quardrivalent vaccine accounted the major market share of xx% reaching upto xx% by 2025. It is expected that trivalent vaccines will phase out in the next few years.

1 Market Introduction
1.1 Introduction
1.2 Scope of Study
1.2.1 Research Objective
1.3 Currency & Pricing
1.4 Limitations
1.5 Assumptions


2 Executive Summary
2.1 Global Influenza Vaccine Market Projection, 2018 – 2025
2.2 Global Influenza Vaccine Market CAGR Growth, By Regions


3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.4.1 Bottom-up Approach
3.4.2 Top-down Approach
3.4.3 Market Breakdown and Data Triangulation


4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 PEST Analysis
4.3.1 Political
4.3.2 Economic
4.3.3 Social
4.3.4 Technological
4.4 Porters Five Forces Analysis
4.5 SWOT Analysis
4.5.1 Strengths
4.5.2 Weaknesses
4.5.3 Opportunities
4.5.4 Threats 


5 Global Influenza Vaccine Market, By Product
5.1 Product Overview
5.1.1 Fluzone/Vaxigrip
5.1.2 Afluria/Fluvirin/Fluad/Flucelvax/Aggripal
5.1.3 Fluarix/FluLaval
5.1.4 FluMist/Fluenz
5.1.5 Other Influenza Vaccines 


6 Global Influenza Vaccine Market, By Type
6.1 Type Overview
6.1.1 Quadrivalent Influenza Vaccines
6.1.2 Trivalent Influenza Vaccines
7 Global Influenza Vaccine Market, By Region
7.1 Regional Overview
7.2 U.S.
7.3 Germany
7.4 UK
7.5 France
7.6 Italy
7.7 Spain
7.8 Japan
7.9 China
7.10 India
7.11 Brazil
7.12 Russia 


8 Company Profiles 


8.1 Sanofi Pasteur Inc.
8.1.1 Company/Business Overview
8.1.2 Financial Overview
8.1.3 Product Benchmarking
8.1.4 Product Pipeline
8.1.5 Key Developments 


8.2 GlaxoSmithKline
8.2.1 Company/Business Overview
8.2.2 Financial Overview
8.2.3 Product Benchmarking
8.2.4 Product Pipeline
8.2.5 Key Development 


8.3 Seqirus
8.3.1 Company/ Business Overview
8.3.2 Financial Overview
8.3.3 Product Benchmarking
8.3.4 Product Pipeline
8.3.5 Key Development 


8.4 AstraZeneca
8.4.1 Company/ Business Overview
8.4.2 Financial Overview
8.4.3 Product Benchmarking
8.4.4 Key Development
8.5 Serum Institute of India Pvt. Ltd.
8.5.1 Company/ Business Overview
8.5.2 Product Benchmarking 


8.6 Abbott
8.6.1 Company/ Business Overview
8.6.2 Financial Overview
8.6.3 Product Benchmarking 


8.7 Pfizer Limited
8.7.1 Company/ Business Overview
8.7.2 Financial Overview
8.7.3 Product Benchmarking 


8.8 Bio Farma
8.8.1 Company/ Business Overview
8.8.2 Product Benchmarking


8.9 Hualan Biological Engineering Inc
8.9.1 Company/ Business Overview
8.9.2 Product Benchmarking
8.9.3 Key Development 


9 Conclusion 

">">